Scholar Rock Holding Corp.

Scholar Rock Holding Corp. uses a TGFβ superfamily platform to develop monoclonal antibodies targeting growth factor activation. Phase 3 Apitegromab (SMA) and Phase 1 SRK‑181 (checkpoint‑resistant cancers) illustrate growth potential across neuromuscular and anemia indications.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 128
HQ: Cambridge

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
SRRK	Scholar Rock Holding Corp. Cap: 4.4B	EQUITY	NMS	USD	US80706P1030	Active	📈